TCTMD - tctmd.com
WEBGiven the growing prevalence of heart failure worldwide, we recognize a clear mandate for developing new monitoring strategies and treatment options to increase survival, decrease hospitalizations, and improve quality of life — and for achieving these goals via a variety of potential interventions that target the various contributors to heart ...
Blood Pressure Insights in COVID-19: Watch for Drops and RAAS …
WEBSep 10, 2020 · Here, Baher Al-Abbasi, MD (University of Miami/JFK Medical Center, Atlantis, FL), and colleagues noted increased in-hospital mortality in 172 COVID-19 patients taking ACE inhibitors or ARBs compared with those not taking the drugs (33% vs 13%; P = 0.003), as well as increased likelihood of admission to the …
STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays …
WEBNov 7, 2022 · CHICAGO, IL—Getting patients up to full doses of guideline-recommended medications within just 2 weeks of an acute heart failure (HF) hospitalization improves measures of congestion and clinical outcomes, the STRONG-HF trial shows. Compared with usual care, rapid uptitration of renin-angiotensin-system (RAS) blockers, beta …
- tctmd.com
WEBA live broadcast from CTO and TVT conferences. Archived versions of all live broadcasts available for 1 year after the end of each meeting. Register. $995. For more information about TCTMD and TCTMD premium memberships, please contact us. Thank you! Free registration or enhanced education options through …
FlowTriever Safe, Effective for Acute PE in Expanded FLASH Results
WEBNov 3, 2021 · For patients with intermediate- or high-risk pulmonary embolism (PE), removing the blockage with the FlowTriever percutaneous mechanical thrombectomy system (Inari Medical) is both safe and effective, according to an expanded interim analysis of the FLASH registry. The procedure provided immediate hemodynamic benefits while patients were still ...
Thoratec Announces Start Of Heartmate III™ U.S. Clinical Trial
WEBSep 9, 2014 · The HeartMate III U.S. clinical trial is a randomized non-inferiority study comparing HeartMate III with HeartMate II®™ and includes a primary endpoint of survival free of device replacement and debilitating stroke. The trial began enrollment in a safety phase under conditional approval from the FDA for 30 patients at five sites.
News | tctmd.com
WEBSubcutaneous Furosemide Enables HF Patients to Address Congestion at Home. The AT HOME-HF pilot study suggests this approach to diuretic delivery can safely improve symptoms and function. By Caitlin E. Cox. September 16, 2024.
Welcome to TCTMD | tctmd.com
WEBOn behalf of CRF and TCTMD, we would like to extend a warm welcome to our community, which has developed over the past 20 years around a common goal to improve the survival and quality of life for people living with cardiovascular disease through research and education. We look forward to seeing you at our conferences and to working together to ...
FDA Approves Shockwave Intravascular Lithotripsy for Calcified ...
WEBFeb 16, 2021 · (UPDATED) The US Food and Drug Administration has cleared the Shockwave intravascular lithotripsy (IVL) system for the treatment of severely calcified coronary artery plaques. The device uses a balloon to deliver sonic pressure waves that can pass through soft arterial tissue to “preferentially …
Slides | tctmd.com
WEBApr 8, 2024 · Interventional Complications 2023. Seattle, WA. July 14. July 15, 2023. See All Conferences. The best online resource for cardiology conference slides around the globe.
Skip to content